Reduction in False-Positive Aspergillus Serum Galactomannan Enzyme Immunoassay Results Associated with Use of Piperacillin-Tazobactam in the United States
Paschalis Vergidis(Mayo Clinic), Chadi A. Hage(Indiana University – Purdue University Indianapolis), John R. Wingard(University of Florida Health), Raymund R. Razonable(Mayo Clinic in Florida), Alison G. Freifeld(University of Nebraska Medical Center), Steven J. Norris(The University of Texas Health Science Center), Richard Köhler(Sidney & Lois Eskenazi Hospital), Thomas J. Walsh(Cornell University), John W. Baddley(University of Alabama at Birmingham), Angela M. Caliendo(Brown University), L. Joseph Wheat(Sidney & Lois Eskenazi Hospital), Hồng Quân Nguyễn(Vietnam National University Ho Chi Minh City), Ryan K. Shields(University of Pittsburgh), Lindsey R. Baden(Brigham and Women's Hospital), Maha Assi(University of Kansas), Pranatharthi Chandrasekar(Wayne State University), Martin B. Kleiman(Riley Hospital for Children), Lynn L. Estes(Mayo Clinic in Arizona)
Cited by 66
Related Papers
Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group
|Clinical Infectious Diseases|2008|4.9k
Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America
|Clinical Infectious Diseases|2015|4k
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
|New England Journal of Medicine|2002|3.3k
Clinical Practice Guidelines for the Management Candidiasis: 2009 Update by the Infectious Diseases Society of America
|Clinical Infectious Diseases|2009|3.2k
Epidemiology and Outcome of Zygomycosis: A Review of 929 Reported Cases
|Clinical Infectious Diseases|2005|3k